APAC IPOs & Placements, Aequitas Research

Clarence Chu

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Lu Daopei Medical Group / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lu-daopei-medical-group" target="_blank" data-smartkarma-citation="entities:36716:1" rel="noopener">Lu Daopei Medical Group (1816743D CH)</a> Lu DaoPei Medical Group is looking to raise around US$400m in its upcoming Hong Kong IPO. The bookrunners are CITIC Securities, CMB International, and Macquarie.</li>
<li>Lu DaoPei Medical Group (LDPM) is a hospital operator focusing on hematology healthcare services.</li>
<li>As per F&amp;S, the firm was the largest hematology healthcare services provider in China in terms of 2021 revenue.</li>
</ul>



Lu Daopei Medical Group (1816743D CH) Lu DaoPei Medical Group is looking to raise around US$400m in its upcoming Hong Kong IPO. The bookrunners are CITIC Securities, CMB International, and Macquarie.
Lu DaoPei Medical Group (LDPM) is a hospital operator focusing on hematology healthcare services.
As per F&amp;S, the firm was the largest hematology healthcare services provider in China in terms of 2021 revenue.


Lu DaoPei Medical Group Pre-IPO Tearsheet

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cdp-holdings-c8e22dc9-b236-4022-88d6-b993574f0c53" target="_blank" data-smartkarma-citation="entities:36715:1" rel="noopener">CDP Holdings (1782198D CH)</a> is looking to raise up to US$400m in its upcoming Hong Kong IPO. </li>
<li>CDP Holding (CDP) is a human capital management (HCM) service provider.</li>
<li>As per CIC, CDP was the No. 1 HCM SaaS+ platform in China in terms of revenue generated from HCM SaaS+ services in 2021.</li>
</ul>



CDP Holdings (1782198D CH) is looking to raise up to US$400m in its upcoming Hong Kong IPO. 
CDP Holding (CDP) is a human capital management (HCM) service provider.
As per CIC, CDP was the No. 1 HCM SaaS+ platform in China in terms of revenue generated from HCM SaaS+ services in 2021.


CDP Holding Pre-IPO - Sales Have Grown but Continues to Rake in Losses

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Alibaba Group Holding  / Equity Capital Markets

<ul>
<li>Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs</li>
<li>On the IPO front,  only the smaller issuers were active with most following through on year end listing plans.</li>
<li>On placements front, HK market got going in a jiffy, riding on the coattails of China reopening.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs
On the IPO front,  only the smaller issuers were active with most following through on year end listing plans.
On placements front, HK market got going in a jiffy, riding on the coattails of China reopening.


ECM Weekly (8th Jan 2022) - Sinohytec, Beauty Farm, Sula, Kfin, Bionote, Meidong, CIFI, Jinxin Fert

Equity, Bottom-up Analyst, Investics Research

Sameer Taneja

Equity, Bottom-up Analyst

Investics Research

It is important to note that the information provided by Investics Research is based on publicly available data and own knowledge, which has been gathered and analyzed from a variety of sources. While every effort has been made to ensure the accuracy and completeness of the information provided, it is not guaranteed to be free from errors or omissions. All forecasts and estimates are based on information that has been obtained from public sources that are considered to be reliable. The sources include but are not limited to, company announcements, exchange filings, presentations, etc. Investics does not guarantee the accuracy and completeness of the forecasts, estimates, and/or other information.

Equity Bottom-up Research

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/china-meidong-auto-holdings-limited" target="_blank" data-smartkarma-citation="entities:10795:1" rel="noopener">China MeiDong Auto (1268 HK)</a> raised 800mn HKD in a top placement (px~15 HKD/share), resulting in a ~4% dilution, citing an opportunistic raise for M&amp;A.</li>
<li>While the company asserts there is a well-defined pipeline, it was not very specific on the size and scope of its targets which was not taken well by the market.</li>
<li>We continue to like the company, trading at a 15x/9x PE FY22e/23e, with a 5.2%/8.8% dividend yield (assuming an 80% payout ratio), with the optionality of M&amp;A potential. </li>
</ul>



China MeiDong Auto (1268 HK) raised 800mn HKD in a top placement (px~15 HKD/share), resulting in a ~4% dilution, citing an opportunistic raise for M&amp;A.
While the company asserts there is a well-defined pipeline, it was not very specific on the size and scope of its targets which was not taken well by the market.
We continue to like the company, trading at a 15x/9x PE FY22e/23e, with a 5.2%/8.8% dividend yield (assuming an 80% payout ratio), with the optionality of M&amp;A potential. 


Meidong: Capital Raise, There's Never a Right Time

China MeiDong Auto / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/china-meidong-auto-holdings-limited" target="_blank" data-smartkarma-citation="entities:10795:1" rel="noopener">China MeiDong Auto (1268 HK)</a> is looking to raise US$100m via a top-up placement.</li>
<li>Proceeds from the offering will be geared towards potential M&amp;A and general working capital purposes.</li>
<li>In this note, we will run the deal through our ECM framework and talk about the recent updates.</li>
</ul>



China MeiDong Auto (1268 HK) is looking to raise US$100m via a top-up placement.
Proceeds from the offering will be geared towards potential M&amp;A and general working capital purposes.
In this note, we will run the deal through our ECM framework and talk about the recent updates.


China MeiDong Auto Placement - Strong Track Record and Past Deals Have Held Up

China

China Meidong Auto Holdings Limited is an automobile dealership and maintenance group in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

China MeiDong Auto (1268 HK)

Lu DaoPei Medical Group Pre-IPO Tearsheet

Lu Daopei Medical Group (1816743D CH) Lu DaoPei Medical Group is looking to raise around US$400m in its upcoming Hong Kong IPO. The bookrunners are...

Clarence Chu

CDP Holding Pre-IPO - Sales Have Grown but Continues to Rake in Losses

CDP Holdings (1782198D CH) is looking to raise up to US$400m in its upcoming Hong Kong IPO. CDP Holding (CDP) is a human capital management (HCM)...

Clarence Chu

ECM Weekly (8th Jan 2022) - Sinohytec, Beauty Farm, Sula, Kfin, Bionote, Meidong, CIFI, Jinxin Fert

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Meidong: Capital Raise, There's Never a Right Time

Despite its capital raise, Meidong is still a great investment, trading at a 15x/9x PE FY22e/23e, with a 5.2%/8.8% dividend yield (assuming an 80%...

Sameer Taneja

China MeiDong Auto Placement - Strong Track Record and Past Deals Have Held Up

China MeiDong Auto (1268 HK) is looking to raise US$100m via a top-up placement. In this note, we will run the deal through our ECM framework and...

Clarence Chu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)